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As early as one month of age, nonobese diabetic (NOD) mice feature pancreatic inﬁltration of autoreactive T lymphocytes, which
destructinsulin-producingbetacells,producingautoimmunediabetes mellitus(T1D)withineightmonths.Thus,wehypothesized
that during the development of T1D, the transcriptional modulation of immune reactivity genes may occur as thymocytes
mature into peripheral T lymphocytes. The transcriptome of thymocytes and peripheral CD3+ T lymphocytes from prediabetic or
diabetic mice analyzed through microarray hybridizations identiﬁed 2,771 diﬀerentially expressed genes. Hierarchical clustering
grouped mice according to age/T1D onset and genes according to their transcription proﬁling. The transcriptional activity of
thymocytes developing into peripheral T lymphocytes revealed sequential participation of genes involved with CD4+/CD8+ T-cell
diﬀerentiation (Themis), tolerance induction by Tregs (Foxp3), and apoptosis (Fasl) soon after T-cell activation (IL4), while the
emergence of T1D coincided with the expression of cytotoxicity (Crtam) and inﬂammatory response genes (Tlr) by peripheral T
lymphocytes.
1.Introduction
Type 1 diabetes (T1D) is an autoimmune disease that results
in the destruction of pancreatic insulin-producing beta cells
[1, 2]. This destruction is a progressive process that occurs
over ﬁve to eight months in the nonobese diabetic (NOD)
mouse or several years in human patients [3]. The early
stages of T1D pathogenesis are characterized by insulitis, an
inﬂammation of the beta cells of the pancreas caused by
lymphocyteinﬁltration. Nevertheless,the molecular genetics
regulating the progress of beta cell failure and factors
determining time of presentation of clinical diabetes are still
poorly understood.
TheNODmouseisanautoimmunemousestrain andisa
primaryanimalmodelusedtodissectthemechanismsoflack
of immune tolerance and autoimmune T1D, which reﬂects
at least a part of human T1D [4–6]. The most important
genetic determinants in susceptibility to diabetes lie in the
major histocompatibility complex (MHC).Within the MHC
locus, the class II molecules DQ8 and DQ2 in humans and
the mouse homologue I-Ag7 in the NOD mouse are thought
to be particularly crucial [7]. In addition, many other genes
have been identiﬁed that contribute to the development of
diabetes in the NOD mouse [8].
In this murine strain, it is now clear that both the CD4+
and CD8+ subsets ofT-cells play a role in the developmentof2 Clinical and Developmental Immunology
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Figure 1: Fluorescent-activated cell sorting (FACS) analysisof thymocytes (approx. 93% purity) (a) and of peripheral CD3+ T lymphocytes
(approx. 87% purity).
disease. Diabetesdoesnotoccurintheabsence ofCD4+ cells,
as shown by studies using anti-CD4 antibodies [9]a sw e l la s
in mice that lack CD4+ T-cells [10], mice that are deﬁcient
in CD8+ cells, either by anti-CD8 antibody injection into
young mice [11], or mice in which few CD8+ T-cells develop
b e c a u s eo fag e n e t i cl a c ko fB e t a - 2m i c r o g l o b u l i n[ 12–14].
These ﬁndings support the idea that T1D is a function of
the action of autoreactive CD3+ T-cells that feature either a
CD4+ or CD8+ phenotype.
The BDC2.5line, which derivesfromaCD4+ T-cell clone
that is restricted by the NOD MHC class II Ag7 molecule
and speciﬁc for an unknown beta cell protein [15, 16], has
beeninstrumental in theelucidationofseveralfeaturesofthe
immunoregulatorygenesorcellsthatcontroltheaggressively
autoreactive T-cells in the periphery [17–20].
The diﬀerentiation into cytotoxic eﬀector cells is the
major function of CD8+ T-cells, which are able to recognize
antigenic peptides in the context of MHC class I molecules.
These peptides are produced through the endogenous
antigen presenting pathways, though evidence suggests that
exogenous antigens are also presented by MHC class I
molecules [21, 22].
The thymus exerts an important role in controlling
autoreactive T-cells. An extremely diverse repertoire of T-
cells is generated through the random rearrangement of T-
cell receptor (TCR) gene segments. This random process
generates autoreactive T-cells that are eventually eliminated
through negative selection, which occurs in the medullar
compartment of the thymic stroma in close association with
the medullary thymic epithelial cells (mTECs). The negative
selection plays an essential role in preventing pathogenic
autoimmune reactions and/or autoimmune diseases.
The mTECs are essentially self-antigen-presenting cells.
These cells express most of the parenchymal organs’ self-
antigens, a phenomenon that has been termed promiscuous
gene expression (PGE) [23, 24]. Thymocytes are in close
interaction with mTECs, establishing the thymic cross-talk.
In fact, the self-antigens are coded from peripheral tissue
antigen (PTA) genes. The translated PTAs are trimmed into
peptides that are presented to thymocytes by means of
the MHC. Dendritic cells also participate in the negative
selection process after they have acquired PTA peptides from
mTECs [23, 25–31].
Thymocyte clones that recognize self-peptide antigens
during the cross-talk phase trigger a death gene expression
cascade and die by apoptosis. Accordingly, the escaping
autoreactive thymocytes from negative selection may cause
severe aggressive reactions in the peripheral tissues and/or
organs, provoking aggressive autoimmunity/autoimmune
diseases. Thus, an imbalance in the central tolerance may
have important consequencesin the pathogenesis of autoim-
mune diseases, including T1D.
The central tolerance imbalance may explain, at least in
part, the results of early studies using anti-CD3 antibodies;
the results indicated that T1D in the NOD mouse is a T-cell-
mediated disease [32].
We considered the following factors in our experiment:
(1) peripheral T-cells represent the primary eﬀectors in
T1D autoreactivity in NOD mice; (2) the role played by
autoreactive T-cells in the periphery may be a consequence
of failure of the negative selection in the thymus; (3)
t h ea u t o r e a c t i v ep h e n o t y p eo ft h e s ec e l l sm a yb ead i r e c t
consequence of their transcriptional activity. Thus, our
interest in this study was to analyze the transcriptome proﬁle
of thymocytes and peripheral CD3+ lymphocytes in the
course of T1D in NOD mice to elucidate the sequential
participation of genes associated with autoreactivity.
2.Materialsand Methods
2.1. Animals, Thymocytes and Peripheral T CD3+ Lymphocyte
Isolation. FemaleNODmicewereborninspeciﬁcpathogen-
free (SPF)conditionsattheCEMIB-UNICAMPanimal facil-
ity of the University of Campinas, SP, Brazil and maintainedClinical and Developmental Immunology 3
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Figure 2: Experimental design of the work discriminatingthe biological samples used (animalgroups and cell types), total RNA extraction,
hybridizations, and microarray data analysis.
in SPF mini-isolators in our laboratory at the University
of S˜ ao Paulo, Campus of Ribeir˜ a oP r e t o ,S P ,B r a z i ld u r i n g
the experiment. We studied prediabetic 1-month-old and
diabetic 7-month-old animals. Diabetes was conﬁrmed by
blood glucose levels (≥250mgglucose/dL) using the Accu-
ChekActivekit(RocheDiagnosticsBrazil,S˜ aoPaulo,Brazil).
The thymi from 1-month-old animals were dissected
and trimmed of fat and connective tissue in DMEM/F10
medium, and thymocytes were obtained by 2-3 passages
of the thymic fragments throughout a 10-μmm e s h
nylon membrane (Sefar Inc. Depew, NY, USA). Pelleted
thymocytes were resuspended in phosphate-buﬀered saline
(PBS). Fluorescent-activated cell sorting (FACS) analysis
in a BD-FACScalibur ﬂow cytometer with phycoerythrin-
(PE-) labeled anti-CD3 antibody indicated that this
procedure yielded approximately 93% purity of the
thymocyte population (Figure 1(a)). These cells were
then used for total RNA preparation.
The peripheral T CD3+ lymphocytes from 1-month-
old prediabetic, 7-month-old prediabetic, or 7-month-old
diabetic animals were isolated from spleens using magnetic
beads for negative selection (Pan T-cell isolation kit, mouse,
Miltenyi Biotec) according to the manufacturer’s instruc-
tions. FACS analysis with PE-labeled anti-CD3 antibody
indicated that this procedure yielded approximately 87%
purity of the CD3+ T lymphocyte population (Figure 1(b)).
These cells were then used for total RNA preparation. The
animal experimental protocol was previously approved by
the Commission for Ethics in Animal Research, Faculty
of Medicine of Ribeir˜ ao Preto, USP, Brazil (Protocol no.
120/2008).4 Clinical and Developmental Immunology
Table 1: Clusters of the diﬀerentially expressed genes and their ontology.
Cluster Biological process Genes
Activation of immune system Cd55 Daf2 Fcer1g Klre1 Klrk1 Lax1 Lyn Malt1 Masp2 Plcg2 Tlr3 Tlr4
Tlr6 Unc93b1
Adaptive immune response Bcl3 Cd55 Cd74 Daf2 Fcer1g Fcgr3 Icam1 Icosl Lilrb3 Masp2 Pou2f2
Slc11a1 Tlr6
Cell activation
Bank1 Bcl11a Bcl3 Btk Casp1 Cd74 Clcf1 Cplx2 Cxcr5 Elf4 Entpd1
Fcer1g Fcgr3 Fyb Gapt Gpr183 H2-M3 Hdac9 Hhex Icosl Il4 Irf1 Irf4
Itgax Klre1 Klrk1 Lax1 Lbp Lilrb3 Lyn Malt1 Plcg2 Pou2f2 Slc11a1
Tlr3 Tlr4 Tlr6 Vwf
Defense response
Alox5 Bcl3 Btk Ccl19 Ccl5 Ccr2 Ccr5 Cd163 Cd180 Cd36 Cd55 Cd74
Chst2 Ciita Clec4a2 Clec4d Cnr2 Daf2 Ddx58 Fcer1g Fcgr3 H2-K1
H2-M3 Hdac9 Il18rap Il1b Irf8 Lbp Lta Ly86 Lyn Malt1 Masp2 Mefv
Ncf1 Neurod2 Pglyrp1 Prg2 Samhd1 Slc11a1 Tirap Tlr3 Tlr4 Tlr6
I-kappa8 kinase/NF-kappa8
cascade Btk Irak2 Malt1 Rel Tirap Tlr4
1 Immune eﬀector process Bcl3 Btk Cd55 Cd74 Cplx2 Daf2 Fcer1g Fcgr3 Icam1 Icosl Lax1 Lbp
Lilrb3 Lyn Masp2 Ncf1 Pou2f2 Slc11a1
Immune response
Bcl3 Btk Ccl19 Ccl5 Ccl9 Ccr2 Cd180 Cd55 Cd74 Ciita Clec4a2
Clec4d Cplx2 Daf2 Ddx58 Enpp1 Fasl Fcer1g Fcgr3 Fcgrt Gpr183
H2-D1 H2-K1 H2-M3 H2-Q10 H2-Q2 H2-Q7 H2-Q8 H2-T23 Hfe
Icam1 Icosl Igj Il18rap Il1b Il4 Irf8 Irf8 Lax1 Lbp Lilrb3 Lta Ltb Ly86
L y nM a l t 1M a s p 2N c f 1O a s 1 bP g l y r p 1P l c g 2P o u 2 f 2P r g 2S a m h d 1
Slc11a1 Tirap Tlr3 Tlr4 Tlr6
Immune response-activating
signal transduction Fcer1g Klre1 Klrk1 Lax1 Lyn Malt1 Plcg2 Tlr3 Tlr4 Tlr6 Unc93b1
Immune system process
Bank1 Bcl11a Bcl3 Btk Casp1 Ccl19 Ccl5 Ccl9 Ccr2 Cd180 Cd300lf
Cd55 Cd74 Ciita Clcf1 Clec4a2 Clec4d Cplx2 Crkl Csf1 Csf3r Cxcr5
Daf2 Ddx58 Dnase2a Elf4 Enpp1 Fasl Fcer1g Fcgr3 Fcgrt Fyb Gapt
Gpr183 H2-D1 H2-K1 H2-M3 H2-Q10 H2-Q2 H2-Q7 H2-Q8
H 2 - T 2 3H d a c 9H f eH h e xI c a m 1I c o s lI g jI l 1 8 r a pI l 1 bI l 4I r f 1I r f 4I r f 8
Itgax Klre1 Klrk1 Lax1 Lbp Lilrb3 Lta Ltb Ly86 Lyn Malt1 Masp2
Myo1e Ncf1 Oas1b Pglyrp1 Plcg2 Pou2f2 Prg2 Samhd1 Slc11a1 Terc
Tirap Tlr3 Tlr4 Tlr6 Tnfrsf13c Unc93b1
Inﬂammatory response
Alox5 Btk Ccl19 Ccl5 Ccr2 Cd163 Cd180 Cd55 Chst2 Cnr2 Daf2
Fcgr3 Hdac9 Il1b Lbp Lta Ly86 Lyn Masp2 Mefv Ncf1 Slc11a1 Tirap
Tlr3 Tlr4 Tlr6
Lymphocyte activation
Bank1 Bcl11a Bcl3 Cd74 Clcf1 Cxcr5 Elf4 Gapt Gpr183 H2-M3
Hdac9 Hhex Icosl Il4 Irf1 Itgax Klre1 Klrk1 Lax1 Malt1 Plcg2 Pou2f2
Slc11a1
Lymphocyte activation during
immune response Bcl3 Gpr183 H2-M3 Plcg2 Slc11a1
Lymphocyte mediated immunity Bcl3 Cd55 Cd74 Daf2 Fcer1g Fcgr3 Icam1 Icosl Lilrb3 Masp2 Pou2f2
Slc11a1
Positive regulation of
interferon-gamma production Bcl3 H2-M3 Irf8 Klre1 Klrk1 Lta Slc11a1 Tlr4
Regulation of defense response A d r b 2A n x a 1C a d m 1C c l 5C c r 5C n r 2C r t a mF c e r 1 gF c g r 3H 2 - B l
H2-M3 Klrb1b Klre1 Klrk1 Lta Nt5e Tgm2 Tlr3 Tlr4 Tlr6 Unc93b1
Regulation of immune eﬀector
process
Cadm1 Crtam Fcer1g Fcgr3 H2-Bl H2-K1 H2-M3 Hmox1 Klrb1b
Klre1 Klrk1 Lta
Regulation of immune response
B t l aC a d m 1C d 5 5C r t a mD a f 2F c e r 1 gF c g r 3H 2 - B lH 2 - K 1H 2 - M 3I l 4
Klrb1b Klre1 Klrk1 Lax1 Lta Lyn Malt1 Masp2 Plcg2 Slc11a1 Tlr3
Tlr4 Tlr6 Tnfrsf13c Unc93b1
Regulation of inﬂammatory
response Adrb2 Anxa1 Ccl5 Cnr2 Fcer1g Fcgr3 Lta Nt5e Tgm2 Tlr4
Regulation of leucocyte mediated
cytotoxicity Cadm1 Crtam H2-Bl H2-K1 H2-M3 Klrb1b Klre1 Klrk1
Apoptosis
Actc1 Bag3 Dapl1 Dedd2 Fasl Gramd4 Hipk2 Nfkb1 Nod1 Pea15a
Pim2 Pmaip1 Psen2 Ripk1 Sgk1 Sgms1Shisa5 Tmem173 Traf1
Traf3ip2 Traf5Clinical and Developmental Immunology 5
Table 1: Continued.
Cluster Biological process Genes
Immune response
B 2 mC c l 3C c l 5C x c l 9E o m e sF a s lF o x p 3H 2 - Q 1 0I l 1 8 r 1I l 1 r l 1I l 7 r
I r g m 1M y o 1 fP f 4P s e n 2T g t p 1T l r 1T m e m 1 7 3T n f a i p 8 l 2T n f s f 8
Traf3ip2
2 Immune system process
B 2 mC c l 3C c l 5C x c l 9E o m e sF a s lF l t 3 lF o x p 3G i m a p 5H 2 - Q 1 0I l 1 8 r 1
Il1rl1 Il2rb Il7r Irf1 Irgm1 Jak3 Myo1f Nfkb1 P2rx7 Pf4 Pik3cd Psen2
Slamf1 Tgfbr2 Tgtp1 Tlr1 Tmem173 Tnfaip8l2 Tnfsf8 Traf3ip2
Regulation of I-kappaB
kinase/NF-kappaB cascade C a r d 6I l 1 r l 1N o d 1P i m 2T g m 2
Regulation of signal transduction
Arhgef12 Arhgef3 Arrb1 Arrb2 Axin2 Card6 Cd44 Fasl Furin Il1rl1
Nod1 P2rx7 Pim2 Psen2 Rasa3 Rasgrp2 Rgs11 Runx2 S1pr1 Smad7
Socs3 Spry2 Tgm2 Zeb2
3 Immune system process
Add2 Ahsp Ank1 Ccl4 Ccr2 Cd48 Cebpa Ctla4 Ctse Elane Epas1
Epb4.2 Gimap5 Gm5077 Id2 Ifng Il1r1 Il1rl1 Il1rl2 Itgam Junb Klf1
Klf11 Mpo Plscr1 Polr3c Samhd1 Spna1 Tal1 Tgtp1 Trim10 Txnrd2
Zbtb32
4 Cell communication
Atg16l1 Bmp8a Cacna1c Cblc Chat Cldn5 Cxcr7 Drd5 Erbb3 Gad1
Gad2 Gast Gja5 Gnal Gpr12 Gpr173 Gpr82 Grp Grpr Hnf1b Itgax
Kcnk2 Lin7a Mrgprb2 Ngfr Olfr1010 Olfr1022 Olfr1048 Olfr107
Olfr1090 Olfr1115 Olfr1161 Olfr128 Olfr1377 Olfr1384 Olfr1388
Olfr1459 Olfr1462 Olfr1469 Olfr1495 Olfr304 Olfr33 Olfr350 Olfr365
Olfr516 Olfr523 Olfr556 Olfr606 Olfr62 Olfr651 Olfr68 Olfr684
Olfr724 Olfr768 Olfr770 Olfr784 Olfr790 Olfr796 Olfr845 Olfr889
Olfr904 Olfr924 Olfr974 Park2 Pdx1 Pik3c2g Plat Pth Rab3b Rab3c
Slc1a2 Slc6a4 Syn2 Taar4 Tacr1 Upk1a Vmn2r26 Vmn2r81 Xcr1
G-protein coupled receptor
protein signalingpathway
Cxcr7 Drd5 Gast Gnal Gpr12 Gpr173 Gpr82 Grp Grpr Kcnk2
Mrgprb2 Olfr1010 Olfr1022 Olfr1048 Olfr107 Olfr1090 Olfr1115
Olfr1161 Olfr128 Olfr1377 Olfr1384 Olfr1388 Olfr1459 Olfr1462
Olfr1469 Olfr1495 Olfr304 Olfr33 Olfr350 Olfr365 Olfr516 Olfr523
Olfr556 Olfr606 Olfr62 Olfr651 Olfr68 Olfr684 Olfr724 Olfr768
Olfr770 Olfr784 Olfr790 Olfr796 Olfr845 Olfr889 Olfr904 Olfr924
Olfr974 Pth Taar4 Tacr1 Vmn2r26 Vmn2r81 Xcr1
Signaltransduction
Bmp8a Cblc Cxcr7 Drd5 Erbb3 Gast Gnal Gpr12 Gpr173 Gpr82 Grp
Grpr Itgax Kcnk2 Mrgprb2 Ngfr Olfr1010 Olfr1022 Olfr1048 Olfr107
Olfr1090 Olfr1115 Olfr1161 Olfr128 Olfr1377 Olfr1384 Olfr1388
Olfr1459 Olfr1462 Olfr1469 Olfr1495 Olfr304 Olfr33 Olfr350
Olfr365 Olfr516 Olfr523 Olfr556 Olfr606 Olfr62 Olfr651 Olfr68
Olfr684 Olfr724 Olfr768 Olfr770 Olfr784 Olfr790 Olfr796 Olfr845
Olfr889 Olfr904 Olfr924 Olfr974 Pdx1 Pik3c2g Plat Pth Rab3b Rab3c
Taar4 Tacr1 Upk1a Vmn2r26 Vmn2r81 Xcr1
Apoptosis, apoptosis regulation
Alms1 Bcl2l1 Birc5 Bub1 Bub1b Casp6 Ckap2 Cul7 E2f1 E2f2 Egln3
Epha2 Fas Ift57 Krt18 Krt8 Lig4 Phlda1 Rad21 Rtn3 Stk3 Tfdp1 Tia1
Tpx2 Traf4 Trp53inp1 Vdac1
Cell activation Ada Bcl11b Ccnd3 Cd4 Cd8a Cxcl12 Fas Hdac7 Hells Lig4 Ly6d Msh6
Patz1 Rag1 Rorc Satb1 Sox4 Themis
5C e l l c y c l e
1190002H23Rik Anapc5 Anln Aspm Aurka B230120H23Rik Birc5
Bub1 Bub1b C79407 Casc5 Ccdc99 Ccna2 Ccnb1 Ccnb2 Ccnd3
Ccne2 Ccnf Ccng2 Cdc20 Cdc25a Cdc25c Cdc45 Cdca2 Cdca3 Cdca5
Cdk1 Cdkn1a Cdkn2c Cdkn3 Cenpe Cenpj Cep55 Chek1 Ckap2
Ckap5 Cul7 E2f1 E2f2 E2f3 E2f7 Ercc6l Esco2 Espl1 F630043A04Rik
Fam33a Fbxo5 Gas2l3 Gsg2 H2afx Haus2 Hells Kif11 Kif2c Kifc1 Lig4
Mad1l1 Mki67 Myb Ncapd2 Ncaph Ndc80 Nde1 Nek2 Nsl1 Nuf2
Nusap1 Pard6g Phgdh Prc1 Psrc1 Pttg1 Rad21 Rad51c Rbbp4 Rcc1
Sgol1 Sgol2Skp2 Spag5 Spc25 Stmn1 Tacc2 Tacc3 Tfdp1 Tpx2
Trp53inp1 Tubb5 Tubg1 Ube2c Uhrf1 Wee16 Clinical and Developmental Immunology
Table 1: Continued.
Cluster Biological process Genes
Cell proliferation A l m s 1A s p mB c l 2 l 1C c n d 3C x c l 1 2G i n s 1H e l l sH m g b 1L i g 4L i p a
M k i 6 7N c a p g 2N d e 1S a t b 1T a c c 2T a c c 3U h r f 1V e g f a
Lymphocyte activation Ada Bcl11b Ccnd3 Cd4 Cd8a Cxcl12 Faz Hdac7 Hells Lig4 Ly6d
Msh6 Patz1 Rag1 Rorc Satb1 Sox4 Themis
Lymphocyte diﬀerentiation Ada Bcl11b Cd4 Cd8a Fas Hdac7 Hells Lig4 Ly6d Patz1 Rag1 Rorc
Satb1 Sox4 Themis
T-cell activation Bcl11b Ccnd3 Cd4 Cd8a Cxcl12 Fas Lig4 Patz1 Rag1 Rorc Satb1 Sox4
Themis
T-cell diﬀerentiation Bcl11b Cd4 Cd8a Fas Lig4 Patz1 Rag1 Rorc Satb1 Sox4 Themis
V(D)J recombination Bcl11b Lig4 Rag1 Xrcc6
CD8-positive, alpha-beta T-cell
diﬀerentiation Pax1 Satb1
Cell diﬀerentiation
Acan Bcl11b Bcl2l1 Bcl6 Bmp7 Cby1 Cdkn1c Cux1 Cxcl12 Dyrk1b
Ephb2 Gjc1 Gpc2 Hdac2 Id3 Ift81 Igfbp3 Lhx2 Lig4 Morc1 Msi2
Myh10 Notch1 Notch3 Ntn1 Paqr5 Pax1 Pias2Pitx2 Ptprf Rag1 Rag2
R u n x 1S a t b 1S o x 1 1S p a t a 6S p o 1 1S t r a 8T b a t aT h y 1W h r n
6 Cell-cell adhesion Acan Arvcf Jup Lmo4 Mcam Ncam1 Ntn1 Ptprf Pvrl3 Vangl2
Lymphocyte diﬀerentiation Bcl11b Bcl6 Lig4 Pax1 Rag1 Rag2 Satb1
Somatic diversiﬁcation and
recombination of T-cell receptor
genes
Bcl11b Lig4
T-cell activation Bcl11b Cxcl12 Lig4 Pax1 Rag1 Rag2 Satb1 Sla2
T-cell diﬀerentiation Bcl11b Lig4 Pax1 Rag1 Rag2 Satb1
T-cell receptor V(D)J
recombination Bcl11b Lig4
V(D)J recombination Bcl11b Lig4 Rag1 Rag2
2.2. Total RNA Preparation. The total RNA was extracted
from 1 ×107 thymocytes or peripheral T CD3+ lymphocytes
using a mirVana total RNA isolation kit (Ambion) accord-
ing to the manufacturer’s instructions. RNA preparations
were conﬁrmed to be free of proteins and phenol by UV
spectrophotometry. The state of degradation was assessed by
microﬂuidic electrophoresis using Agilent RNA Nano 6000
chipsandan Agilent2100Bioanalyzer(AgilentTechnologies,
Santa Clara, CA, USA). Only RNA samples that were free of
proteins and phenol and featured an RNA Integrity Number
(RIN) ≥ 9.0 were used.
2.3. RNA Ampliﬁcation, Labeling, Microarray Hybridiza-
tion and, Data Analysis. Changes in gene expression were
evaluated using the Agilent one-color (Cy3 ﬂuorochrome)
microarray-based gene expression platform according to the
manufacturer’s instructions. For hybridization onto whole
mouse genome 4 × 44K 60-mer oligonucleotide arrays
(G4122F, Agilent Technologies, Palo Alto, CA, USA), 500 ng
total RNA was used in the one-color Quick Amp labeling
kit (Agilent Technologies, Santa Clara, CA, USA). Samples
of complementary RNA (cRNA) were hybridized for 18h at
42◦Cin arotatorovenand werethenwashed. Thearray slides
were scanned using a DNA microarray scanner (Agilent
Technologies), and the hybridization signals were extracted
using the Agilent Feature Extraction software version 10.5.
Gene expression proﬁles from independent preparations
of thymocytes (from 1-month-old prediabetic mice) or
CD3+ peripheral lymphocytes (from 1-month-old predi-
abetic, 7-month-old prediabetic or 7-month-old diabetic
mice) were analyzed through comparisons of the microarray
hybridizations of the respective samples. Figure 2 depicts
the experimental design for further comparison of the gene
proﬁling.
A complete ﬁle that provides all of the genes present in
t h em i c r o a r r a yu s e di nt h i ss t u d y ,a sw e l la st h ee x p e r i m e n t a l
conditions, is available online at the MIAME public database
[33], ArrayExpress accession E-MEXP 3047.
The microarray numerical quantitative data were nor-
malized to the 75th percentile and were analyzed using the
GeneSpring GX bioinformatics platform [34] according to
the default instructions allowing hierarchical clustering of
samples ofmiceor genesbased onANOVAstatistical analysis
(P<. 01) with a fold change >2.0 and an uncentered Pearson
correlation metrics [35]. The similarities and dissimilarities
in gene expression are presented as dendrograms, in which
the pattern and length of the branches reﬂect the relatedness
of the samples or genes, and heat maps.
2.4. Gene Ontology. Microarray data analysis was used to
identify gene expression based on combined information
from the public databases DAVID [36] and SOURCE [37].
These databases show gene annotation enrichment analysis,
functional annotation clustering, BioCarta and KEGG path-
way mapping (DAVID), or microarray data and sequencingClinical and Developmental Immunology 7
Cluster 1
Cluster 2
Cluster 3
Cluster 4
Cluster 5
Cluster 6
CD3+ diabetic ≥ 7month
CD3+ pre diabetic 7month
CD3+ pre diabetic 1month
CD3+ thymocytes 1month
Figure 3: Hierarchical clustering of thymocytes and peripheral
CD3+ lymphocytes of nonobese diabetic (NOD) mice based on
microarray gene expression proﬁling. Dendrograms and heat maps
were obtained using the Cluster-Tree View program within the
GeneSpring GX (Agilent) platform. Red = upregulation, green =
downregulation, and black = unmodulated (Pearson correlation
metrics, 75 percentile). The 2,771 diﬀerentially expressed genes
were divided in six clusters (clusters 1 to 6) according to their
relative expression levels and ontology.
of cDNA clones from diﬀerent organ/tissues (SOURCE),
including GenBank accession number, chromosomal loca-
tion and the molecular/biological function of each gene
analyzed.
2.5. Oligonucleotide Primer Design and Quantitative Real-
Time Polymerase Chain Reaction (qRT-PCR). Microarray
data were conﬁrmed using qRT-PCR for the genes
listed below that were diﬀerentially expressed between
thymocytes and peripheral CD3+ Tl y m p h o c y t e s .T h ec D N A
sequences of these genes were retrieved from the NCBI
GenBank database (http://www.ncbi.nlm.nih.gov/genbank/
GenbankSearch.html), and the Primer3 web tool (http://
biotools.umassmed.edu/bioapps/primer3 www.cgi) was
used to select pairs of oligonucleotide primers spanning
an intron/exon junction and with consideration of the
alternative transcripts. An optimal melting temperature
of 60◦C was standardized for all genes. The following
forward and reverse sequences are given in the 5  to 3 
orientation: Hypoxanthine phosphoribosyltransferase 1
(HPRT1, accession number NM 000194.2, GACCAGTCAA
CAGGGGACAT  and CTGCATTGTTTTGCCAGTGT); Fas
ligand (Fasl, accession number NM 000639, ACTCCGTG
AGTTCACCAACC and GTGGGGGTTCCCTGTTAAAT);
Toll-like receptor 3 (Tlr3, accession number BC068487,
TTGTCTTCTGCACGAACCTG and CCCGTTCCCAACTT
TGTAGA); Toll-like receptor 4 (Tlr4, accession number
NM 138554, TCAGAACTTCAGTGGCTGGA CCTGGGGA
AAAACTCTGGAT); Forkhead box P3 (Foxp3, accession
number NM 014009, TCTTCGAGGAGCCAGAAGAG and
GCTCCAGAGACTGCACCACT);Thymocyteselectionasso-
ciated (Themis, accession number NM 001164685, AAATG
AAGCTCACCTTGCTCA and ATCCTGGCCACTTTCATC
TG). HPRT1 was used as the constitutively expressed gene.
Transcriptional expression levels were determined using
a StepOne Real-Time PCR System (Applied Biosystems,
USA). The ΔΔCT relative normalization method was used
as described previously. We used the GraphPad Prism 5.00
tool (http://www.graphpad.com/prism/Prism.html) to run
one-way or two-way ANOVAs with Bonferroni’s correction
statistics.
3.Results
Although the expression pattern remained unchanged
between thymocytes and peripheral T lymphocytes from
prediabetic and diabetic animals for the majority of the
44,000 sequences tested, which presented a control/test ratio
≈ 1.0 (Pearson correlation), 2,771 genes were found to be
diﬀerentially expressed. Hierarchical clustering of the data
allowed for the identiﬁcation of clusters of upregulated
(induced) and downregulated (repressed) genes. Changes in
gene expression proﬁle could be observed when comparing
thymocytesfrom1-month-oldprediabeticmicewithperiph-
eral CD3+ lymphocytes from 1-month-old prediabetic, 7-
month-old prediabetic, or 7-month-old diabetic mice to
observe the modulated genes that coincided with the devel-
opment of T1D.8 Clinical and Developmental Immunology
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Figure 4: Conﬁrmation of microarray data by qRT-PCR. The Fasl, Tlr3, and Tlr4 genes were downregulated in thymocytes from prediabetic
animals, Foxp3 was upregulated in peripheral CD3+ lymphocytes from diabetic animals, and Themis was upregulated in thymocytes from
prediabetic animals.Clinical and Developmental Immunology 9
Hierarchical clustering analysis depicted in Figure 3
shows variability in the hybridization signatures between
cell types. The upper horizontal dendrogram (cell samples)
demonstrates that this variability could distinguish cells
according to their developmental phase, namely, thymocytes
(prediabetic animals) from peripheral CD3+ lymphocytes
(prediabetic and diabetic animals). The left vertical den-
drogram shows the genes that were diﬀerentially expressed
(up- or downregulated) according to their respective bio-
logical function, and the genes were divided into six
clusters (Figure 3 and Table 1). Clusters 1 to 4 contain
genes downregulated in thymocytes and peripheral CD3+
lymphocytes from 1-month-old prediabetic animals and
progressively upregulated in peripheral CD3+ lymphocytes
from 7-month-old prediabetic and diabetic animals.
Cluster 1 comprises 767 diﬀerentially expressed genes,
and the following genes were highlighted because they
participateinimmuneprocessespotentiallyimplicatedinthe
pathogenesis of T1D: IL4, involved with T-cell activation,
Crtam, involved in cytotoxicity and Tlr3, Tlr4, and Tlr6,
involved in inﬂammatory response.
Cluster 2 comprises 340 diﬀerentially expressed genes,
and the following genes were highlighted: Fasl, involved
in the induction of apoptosis by extracellular signals and
FoxP3, involved in CD25+ alpha-beta T-regulatory (Treg)
cell diﬀerentiation and positive regulation of T-cell tolerance
induction.
Cluster 3 comprises 435 diﬀerentially expressed genes,
and the following genes were highlighted: Chemokine (C–
C motif) ligand 4 gene (Ccl4) and Chemokine (C–C motif)
receptor 2 gene (Ccr2), both involved in inﬂammatory
response; CD48 antigen gene, involved in T-cell activation;
Cytotoxic T-lymphocyte-associated protein 4 gene (Ctla4),
involved in negative regulation of Treg cell diﬀerentiation;
Interferon gamma gene (Ifng), involved in positive regula-
tion of T-cell proliferation; Integrin alpha M gene (Itgam),
involved in cell-cell adhesion.
Cluster 4 comprises 292 diﬀerentially expressed genes,
and the following genes were highlighted: Integrin alpha
X (Itgax) and Claudin 5 (Cldn5) gene, involved in cell-
cell adhesion; Gap junction protein, alpha 5 (Gja5) gene,
involved in cell-cell signaling; HNF1 homeobox 1 transcrip-
tion factor, involved in maturity onset diabetes of the young
and circadian regulation of transcription; and Gastrin (Gast)
and Guanine nucleotide-binding protein 1 (Gna1) gene,
bothinvolvedinprotein signaling pathway.Interestingly, this
cluster comprises various members of the olfactory receptor
(Olfr) gene family, which is involved with cell signaling
pathways.
Finally, clusters 5 and 6 comprise 610 and 327 genes,
respectively, which feature a diﬀerent expression pattern
than those included in the previous clusters, that is, they
were mainly upregulated in thymocytes from prediabetic
mice and progressively downregulated in peripheral CD3+
lymphocytes from prediabetic and diabetic animals. These
two clusters contain genes involved in CD4/CD8 cell dif-
ferentiation (Themis) and V(D)J recombination (Rag1 and
Rag2).
Using qRT-PCR, we assayed the expression levels of ﬁve
diﬀerentially expressed genes (Fasl, Tlr3, Tlr4, Foxp3 and
Themis) that are associated with thymocyte selection, T-
cell diﬀerentiation, cell activation, or inﬂammation. The
expression levels obtained with qRT-PCR method were
comparable with microarrays, for example; the Fasl, Tlr3
and Tlr4 genes were downregulated in thymocytes from
prediabetic animals, Foxp3 was upregulated in peripheral
CD3+ lymphocytes from diabetic animals, and Themis
was upregulated in thymocytes from prediabetic animals
(Figure 4).
4.Discussion
In this study, we assessed the hypothesis that the transcrip-
tional modulation of immune reactivity genes may occur
during the development of T1D as thymocytes mature into
peripheral T lymphocytes. Consequently, the emergence of
T1D might follow a pattern of the transcriptional activity
of these cells, sequentially featuring genes associated with a
negative selection of thymocytes, T-cell maturation, diﬀer-
entiation, and autoreactivity.
As discussed in a previous study [38], diabetes in NOD
mice is similar to T1D patients, and the progress of diabetes
in these animals occurs in two stages. In the ﬁrst stage,
autoreactive CD8+ T lymphocytes inﬁltrate the pancreatic
islet by 1 month after the birth. However, most pancreatic
islets are preserved at this phase, and the animals are
clinically healthy. Stage one can persist for months because
the autoimmune attack is under control and is relatively
nondestructive. In the second stage, most of pancreatic islets
are destructed and animals are often diabetic.
Because these animals spontaneously develop autoim-
munediabetes mellitus thatis similar tohumanT1D,includ-
ing the presence of pancreas-speciﬁc autoantibodies and
autoreactive CD4+ or CD8+ T-cells and synteny to human
chromosomal linkage groups associated with T1D, they are
a classical model system for investigating autoimmune T1D
and/or failure in the tolerance mechanisms [4, 6, 28]. Thus,
we chose to employthe NODmouse as a model system given
the diﬃculty of easily testing this theory in humans.
To exclude the inﬂuence of genetic backgrounds of
nonautoimmunemousestrains, wecomparedonlygroupsof
NOD mice in two distinct phases of autoimmunity, namely,
prediabetic (1- or 7-month-old) and diabetic (≥7-month-
old).
Moreover, by establishing transcriptome comparisons
between cells from prediabetic and diabetic animals or
between thymocytes and peripheral T lymphocytes, it was
possible to ﬁnd genes temporally regulated (because T1D
emerges according to age) and regulated according to T-cell
development.
The procedures for isolation of thymocytes and periph-
eral CD3+ T lymphocytes used in this work yielded purities
(approximately 93% for thymocytes and 85% for peripheral
CD3+ T lymphocytes) that are comparable to automated cell
sorting of T-cells. Moreover, the peripheral CD3+ Tl y m -
phocytes were isolated by negative separation, minimizing
eventual cell activation by artifacts.10 Clinical and Developmental Immunology
Figure 3 (clusters 1 to 4) and Table 1 show the gene
expression pattern observed in thymocytes and peripheral
CD3+ lymphocytes from prediabetic 1-month-old animals.
T h eg e n ee x p r e s s i o ni nt h e s ec e l l sc o u l db ec o n s i d e r e d
to occur in the ﬁrst stage of T1D, and this expression
features the down-regulation of genes involved with the
activation of the immune system/adaptive response, cell
activation, NF-KappaB cascade, immune eﬀector/immune
responseprocesses,inﬂammatory response,lymphocyteacti-
vation, the regulation of interferon-gamma production, the
regulation of leukocyte-mediated cytotoxicity,apoptosis, cell
communication, and signal transduction. Altogether, these
biological processes are necessary for the development of
lymphocyte diﬀerentiation and autoreactivity.
The thymocytes from prediabetic 1-month-old animals
featured down-regulation of genes associated with several
biological processes that were gradually upregulated in the
peripheral CD3+ lymphocytes from prediabetic 1-month-
old, prediabetic 7-month-old, and diabetic 7-month-old
animals (Figure 3 and Table 1). Among these processes
and their respective genes, we selected some of the most
important to discuss because of their direct or indirect
association with aggressive autoimmunity.
TheapoptosisprocessfeaturedgenesincludingFasligand
(Fasl), TNF receptor-associated factor (Traf1 and Traf5),
Traf3 interacting protein 2 (Traf3ip2), and Tumor necrosis
factor (ligand) superfamily, member 8 (Tnfsf8 or TRAIL).
Because apoptosis is the ﬁnal stage of the negative
selection of thymocytes in the thymus [29], the down-
regulation of these genes may favor the survival of autore-
active thymocyte clones, including those that recognize
pancreatic beta cell autoantigens.
Ar o l ef o rT R A I Li nT 1 Di nN O Dm i c eh a sb e e n
evidenced by its blockade with consequent exacerbation of
the disease [39] and by its systemic delivery indicating that
T1D can be prevented by TRAIL overexpression through an
enhancementofthetissueinhibitorofthemetalloproteinase-
1( T I M P - 1 )f u n c t i o n[ 40]. The authors concluded that
elevated TIMP-1 production inhibits the activity of matrix
metalloproteinases, which may contributeto the suppression
of the transmigration of diabetogenic T-cells into the pan-
creaticisletsandprotectspancreaticbetacellsfromcytokine-
induced apoptosis.
The tolerance induction process featured Forkhead
b o xP 3( F o x p 3 )g e n e ,w h i c hw a sa l s od o w n r e g u l a t e di n
thymocytes from 1-month-old prediabetic animals. This
gene is involved in tolerance induction via CD4+CD25+
T-regulatory cells (Tregs) [41–43], a process that directly
activates any ofthe stepsrequired fortolerance, a physiologic
state in which the immune system does not react destruc-
tively against self-components. Thus, their deregulation may
impair the Treg-mediated suppression of aggressive autoim-
munity, favoring the survival of autoreactive thymocytes in
the thymus.
The T-cell activation process featured several downreg-
ulated genes in thymocytes from 1-month-old prediabetic
animals, from which we highlight Chemokine (C–C ligand
motif) ligand 4 (Ccl4), Chemokine (C–C motif) receptor
2 (Ccr2), Cd48 antigen and Interferon, gamma (Ifng), and
Interleukin 4 (IL4) genes. These genes were gradually upreg-
ulated in peripheral CD3+ lymphocytes from prediabetic
to diabetic animals and may increase the activation of
autoreactive T-cell clones in the periphery.
Interestingly, the G-protein-coupled receptor protein
signaling pathway and signal transduction processes shared
several members of the olfactory gene family (Olfr), which is
involvedinsensory perceptionofsmell through receptorand
signaltransduceractivity.Thetwopathwaysalsoshared bone
morphogenetic protein 8a (Bmp8a) gene, which is involved
in growth and ossiﬁcation. These genes were downregulated
in thymocytes from 1-month-old prediabetic animals and
were gradually upregulated in peripheral CD3+ lymphocytes
from prediabetic to diabetic animals. Despite their disparate
biological processes in the context of T1D, these genes may
play a role in the receptor-mediated signal transduction
activity of peripheral T-cells in diabetic animals.
Dissimilar from the pattern of genes related to the
processes discussed above, the T-cell receptor V(D)J recom-
bination and CD4+/CD8+ T-cell diﬀerentiation featured
genes were upregulated in thymocytes and CD3+ peripheral
T lymphocytes from prediabetic 1-month-old animals and
were gradually downregulated in peripheral CD3+ lympho-
cytes from prediabetic and diabetic 7-month-old animals.
Among these genes, we highlight the recombination
activating genes (Rag-1 and Rag-2) that code the recom-
binase catalytic complex involved in the recognition of
recombination signal sequences (RSS) within the T-cell
receptor loci (TCR alpha, beta, gamma or delta), cutting
and recombining DNA during aleatory generation of TCR
diversity. The generation of TCR diversity implies the
production of T-cell clones directed to foreign antigens and
also autoreactive clones. Autoreactive clones are normally
eliminated by apoptosis throughout the negative selection
process.
Also,Adenosinedeaminase (Ada)gene,which isinvolved
in a process that increases the frequency of T-cell diﬀerenti-
ation in the thymus, and CytotoxicT-lymphocyte-associated
protein 4 (Ctla4) gene, which in contrast to Ada gene, is
involved in the negative regulation of T-cell proliferation,
were both identiﬁed.
Finally, we found the Thymocyte selection associated
(Themis) gene, which is expressed in the thymus and
to a lesser extent in the spleen but is not detectable
in nonlymphoid tissues. This gene is highly expressed in
thymocytes between the pre-T-cell antigen receptor (pre-
TCR) and positive-selection checkpoints and is expressed at
a low level in mature T-cells (at the protein level). Themis
is also implicated in the control of T-helper CD4+/cytotoxic
CD8+ cell fate. Moreover, the CD4 as well as CD8a antigen
genes, which deﬁne the respective T-helper CD4+ or T
cytotoxic CD8+ phenotypes, were also found.
Duringtheir permanence within the thymus,thymocytes
activate a developmentally complex mechanism because of
close contact with thymic stroma. The medullary thymic
epithelial cells (mTECs), which form the stromal medullar
compartment, present peripheral tissue antigens (PTAs) to
thymocytes to eliminate autoreactive clones by inducingClinical and Developmental Immunology 11
apoptosis (negative selection),leading totolerance induction
[23, 24].
Failure in the expression of speciﬁc PTA genes in
the thymic stroma is strongly associated with aggressive
autoimmunity as recently observed during the development
of T1D in NOD mice [38] or collagen-induced arthritis
in DBA-1/J mice [44]. This indeed led to survival of
autoreactive thymocyte clones that once in the periphery,
mediate autoimmune attack of target structures such as
pancreatic beta cells.
To better understand the control of transcriptional activ-
ity of thymocytes speciﬁcally associated with the induction
of tolerance and negative selection within the thymus or
cytotoxicity and inﬂammatory response in peripheral T
lymphocytes,we proposefurther experimentstoevaluatethe
participation of microRNAs (miRNAs) that once dysregu-
lated might be associated with aggressive autoimmunity of
T1D.
5.Conclusion
In this study, we were able to construct a transcriptional
proﬁle of T-cell development comparing thymocytes with
peripheral CD3+ lymphocytes in the context of the emer-
gence of T1D. The sequential participation of genes involved
with the main steps of T-cell development such as the gener-
ation of TCR diversity, CD4+/CD8+ cell fate, apoptosis, and
negative selection demonstrated that the T1D autoimmune
phenotype in NOD mice runs in parallel with transcriptome
changes of T-cells. The results obtained conﬁrm our initial
hypothesis.
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